Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00489791 for albuminuria reduction in adults with type 2 diabetes and overt nephropathy
2010-021358-20Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis, chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing PF-00489791 once daily with Placebo once daily (2 arms). Primary endpoint: Urinary albumin:creatinine ratio. Started Oct 2010; status: completed.
02
Drugs
PF-00489791
03
Conditions
diabetic glomerulosclerosischronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-021358-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021358-20.